Dataroom
SearchDetermined.
Focusing on the development of new drugs for the treatment of inflammatory diseases
Our mission
Temisis is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing a strong inflammatory component.
Temisis is committed to developing small therapeutic molecules to fulfil unmet needs in pathologies involving IL-17/23 axis of inflammation.
News
Share with us on Derm Drug Development Summit 2019 during our talk about TEM1657 – A Novel Small Molecule Approach Targeting Psoriasis.
Technology
Our main asset in dermatology, TEM1657, is a brand-new small molecule that shows similar efficacy as market reference corticosteroids at pre-clinical stage to remit psoriasis symptoms but without the common side effects that are associated.
1
Rapid efficacy
Symptoms are significantly reduced after the first application of TEM1657.
2
Complete remission of psoriasis symptoms
No erythema – Regulated desquamation – Normal skin thickness.
3
No side effect
No skin thinning (unlike corticosteroids), no observed side effect on animals in toxicity tests.
Dataroom
Temisis is sharing latest non-confidential data about the development of TEM1657 with interested partners and potential investors.
Contact us
19 av de la Forêt de Haye,
54500 Vandœuvre-lès-Nancy
France
Tel.: +33 (0) 383 940 342
contact@temisis.com
www.temisis.com
